Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer
- DOI
- 10.20517/cdr.2022.31
- Published
- 2022
- Container
- Cancer Drug Resistance
- Publisher
- OAE Publishing Inc.
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.20517/cdr.2022.31,
title = {Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer},
author = {Amy H. Tang and Richard A. Hoefer and Mary L. Guye and Harry D. Bear},
year = {2022},
journal = {Cancer Drug Resistance},
doi = {10.20517/cdr.2022.31},
url = {https://doi.org/10.20517/cdr.2022.31}
}RIS
TY - JOUR TI - Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer AU - Amy H. Tang AU - Richard A. Hoefer AU - Mary L. Guye AU - Harry D. Bear PY - 2022 JO - Cancer Drug Resistance DO - 10.20517/cdr.2022.31 UR - https://doi.org/10.20517/cdr.2022.31 ER -
APA
Tang, A. H., Hoefer, R. A., Guye, M. L., & Bear, H. D. (2022). Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer. Cancer Drug Resistance. https://doi.org/10.20517/cdr.2022.31
Source records
- crossref · retrieved 2026-09-26T15:07:29.793Z